study question: Is it feasible to deliver anastrozole (ATZ), an aromatase inhibitor (AI), by a vaginal polymer-based drug delivery system in the cynomolgus monkey (Macaca fascicularis) to describe the pharmacokinetic profile?
Introduction
The vagina is a suitable site of local and systemic drug administration (Mishell et al., 1970) . Drugs absorbed from the vagina do not undergo first-pass metabolism because blood leaving the vagina enters the peripheral circulation via a rich venous plexus, which empties primarily into the internal iliac veins (Richardson et al., 1992; Hussain and Ahsan, 2005) . Diverse options of intravaginal delivery formulations and systems are used for drug administration such as tablets and suppositories, creams and gels and the intravaginal rings (IVR) (Hussain and Ahsan, 2005) . The vaginal drug delivery systems are used to provide sustained and controlled drug release most often for contraceptive steroid hormones (Brache and Faundes, 2010) and hormone replacement therapy (Ballagh, 2001) . The advantages of intravaginal drug delivery are manifold if compared with oral administration of drugs, such as the prolonged release and the advantage to use less drug to gain equivalent pharmacodynamic efficacy (Mishell et al., 1970) plus the circumvention of the liver first pass. One additional aspect is that the constant release rates minimize the peak to trough ratio of serum drug levels which may be of importance for Cmax-driven effects (wanted and un-wanted). Furthermore, self-administration of IVRs with longer dosing intervals is perceived as more convenient by some patients compared with daily intake of a pill, and therefore increases the compliance of patients (Novak et al., 2003; Alexander et al., 2004) .
Drugs in an IVR formulation are well suited to treat gynecological diseases like endometriosis, a chronic inflammatory disease that affects 5 -10% of women of reproductive age, often associated with a devastating impact on their quality of life (Giudice and Kao, 2004) . Estrogen deprivation is a clinically proven concept for the treatment of endometriosis. However, none of the approved therapies for endometriosis is able to block endometriotic estrogen production. Thus, blocking the aromatase as a key enzyme of estrogen biosynthesis (Noble et al., 1996) may provide an attractive alternative treatment option, and was shown to be effective in treatment of endometriosis in preclinical models (Altintas et al., 2010; Bilotas et al., 2010; Streuli et al., 2012) . Furthermore, evidence for therapeutic efficacy of aromatase inhibitors (AI) in endometriosis was demonstrated in several exploratory clinical trials (for a review of the clinical experience, see (Ferrero et al., 2011) ).
Anastrozole (ATZ) is an AI that was developed by Zeneca (now AstraZeneca) Pharmaceuticals under the brand name Arimidex TM for the treatment of hormone-sensitive breast cancer in post-menopausal women (Plourde et al., 1994) . Clinical evidence for the use of ATZ in endometriosis showed that 1 mg of ATZ in combination with a combined oral contraceptive (levonorgestrel (0.1 mg/day)/ethinylestradiol (0.020 mg/day)) resulted in a significant reduction of endometriosisassociated pelvic pain (Amsterdam et al., 2005) . Thus, an IVR releasing continuously ATZ may provide an attractive new pharmaceutical option for the treatment of endometriosis.
The primary objectives of the present study were to show compatibility of ATZ with a polymer-based vaginal drug delivery system, to get first insights into the in vitro and in vivo release and the pharmacodynamic effects of intravaginally administered ATZ in a relevant preclinical endocrine model. Additionally, ATZ was administered intravenously to cynomolgus monkeys in order to provide the necessary pharmacokinetic parameters for the calculation of the in vivo release rates of the IVRs and the in vitro/in vivo correlation.
Materials and Methods

Anastrozole
Anastrozole, 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile was bought from OChem Incorporation, IL, USA.
IVRs
IVRs for the cynomolgus monkey, with an outer diameter of 14 mm, releasing three different doses of ATZ (doses A-C, Table I ) were designed and tested for in vitro/in vivo release for up to 42 days as described in the published patent WO2011/120925.
In vitro release of ATZ from the IVR
The in vitro release rate of ATZ from the IVRs was tested in 75 ml of 1% hydroxy-propyl-beta-cyclo-dextrin-water solution in shakers at 378C. Sampling was performed daily except for week-ends. The concentration of ATZ was analyzed by high performance liquid chromatography with UV detection (HPLC-UV). Additionally, ex vivo ring residual drug content of the IVRs was measured at the end of the study by extraction of the worn rings with tetrahydrofuran and analyzed by HPLC-UV.
Ethical approval
Cynomolgus monkeys (Macaca fascicularis) (purpose bred animals, Hartelust BV, Tilburg, NL) aged 5 -6 years were housed according to the EU guideline 2010/63 EU. The study (study code: A 0451/09) was approved by the German animal welfare authorities (LAGeSo, Berlin).
Animals
The menstrual cycle of the cynomolgus monkeys was monitored for at least 6 months. The mean weight of the animals at study start was 3.8 + 0.78 kg. Only animals with a regular cycle were included in the study (n ¼ 5 /group). Ex vivo ring residual drug content 1.1 + 0.1 4.9 + 0.5 32.8 + 1.5
Css, mean steady state plasma concentration; CL, plasma clearance.
Analytical methods to measure plasma levels of ATZ in cynomolgus monkeys
An HPLC method with tandem mass spectrometry was developed to determine ATZ levels in plasma of cynomolgus monkeys. Blood samples containing Li-heparin were collected at least every third day during the study period (see below for more details) and plasma was prepared by centrifugation. Monkey plasma samples containing the analyte and an internal standard were extracted using a liquid-liquid extraction procedure, evaporated to dryness, reconstituted, and analyzed by HPLC equipped with an AB Sciex API 4000 mass spectrometer (LC -MS/MS). Positive ions were monitored and quantification was performed employing the peak area ratio. The lower limit of quantification (LLOQ) of the method was 0.15 mg/l.
Pharmacokinetic evaluation after IVR insertion and intravenous application
For pharmacokinetic evaluation of the IVR in monkeys, plasma samples were taken once daily from Day 1 to 3 and afterwards every third day until menses occurred (17-42 days). The steady state plasma concentration (C ss ) was calculated as mean concentration of all time points between 24 h and the last measured time point (ca. 30 days). ATZ was administered by intravenous infusion (15 min) at a dose of 0.2 mg/kg in 50% polyethylene glycol (PEG)400 to female cynomolgus monkeys (n ¼ 3). Plasma samples were taken over 24 h and analyzed for ATZ levels by LC -MS/MS. Pharmacokinetic evaluation of the concentration versus time data was performed by noncompartmental (moment) analysis using an in-house software tool called KinEx. The pharmacokinetic evaluation method is in accordance with the Global Operational Manual 'BPD-OI-039' of Bayer HealthCare 'NonCompartmental Analysis (NCA) in Pharmacokinetics (PK)'. In vivo release rate from the IVRs was calculated as the product of the mean steady state plasma concentration (C ss ) after IVR administration and in vivo plasma clearance (CL) obtained from intravenous administration (Release Rate ¼ Css × CL).
Pharmacodynamic study of ATZ IVRs
In order to evaluate the pharmacodynamic effect of intravaginally applied ATZ, intact cynomolgus monkeys were used to study the dose-dependent impact of ATZ on hormone levels. ATZ was applied by IVRs at three dose levels, based on their in vitro release rates (n ¼ 5/group). IVRs were fixed with a suture loop within the vagina for one menstrual cycle. During the treatment period, blood samples were collected at least every third day. To assess the pharmacodynamic effect, estradiol (E2), estrone (E1), progesterone, FSH, LH, testosterone and androstenedione-levels were investigated, with E2 as the major surrogate for treatment efficacy. The hormones were measured by radioimmunoassay according to the manufactures guidelines (E2 (J125-DAK/Diagnostic Systems Laboratories, Switzerland), FSH (J125-DAK/Schering, Germany), E1 (J125-DAK/Diagnostic Systems Laboratories, Switzerland), androstenedione (J125-CT/Diagnostic Systems Laboratories, Switzerland), testosterone (J125-CT/Diagnostic Systems Laboratories, Switzerland), progesterone (J125-CT/Siemens, Germany), LH (J125-DAK/Schering, Germany)). Twice weekly monitoring of the ovaries for the development of ovarian cysts was done with ultrasound imaging by using the Philips/ATL HDI 5000 system. Animals (1/group) that removed the IVRs during the study were not included into the analysis of the pharmacodynamic parameters, but partially until the time of the removal for the pharmacokinetic analysis.
Statistical analysis
All statistical analyses including calculation of mean values and standard deviations (SD) were performed by using the software GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA). The logarithm of the observed hormone levels was taken in order to reduce the influence of skewed data distributions on the analysis of mean values per treatment group. Dose groups were compared with the corresponding vehicle group using a two-sided t-test approach using an alpha-level of 5%. Due to the exploratory nature of the experiment, statistical group comparisons were not adjusted for multiplicity.
Results
In vitro release of ATZ Different combinations of ATZ-containing vaginal rings were tested providing three different in vitro release rates of ATZ (doses A -C) ( Fig. 1 and Table I ). The initial (Day 1) release rates from these rings were found to be 26 mg/day (dose A), 85 mg/day (dose B) and 390 mg/day (dose C). The mean release rates from Day 2 to Day 30 were 16, 64 and 306 mg/ day for doses A-C, respectively. A sustained release was achieved for the tested period (42d) with a decline in released ATZ (d1-d4 versus d24-d28) from 22 to 12 mg/day (dose A), 79 to 54 mg/day (dose B) and 361 to 271 mg/day (dose C).
In vivo intravenous pharmacokinetics of ATZ ATZ was administered i.v. at a dose of 0.2 mg/kg (n ¼ 3). A plasma clearance of 0.58 l/h/kg, a steady-state volume of distribution of 1.7 l/kg and a half-life of 1.8 h was calculated (Table II and Fig. 2 ).
In vivo release and pharmacodynamic effects of ATZ vaginal rings
The in vivo release and the pharmacodynamic activity of vaginally administered ATZ were investigated in healthy female cynomolgus monkeys in three different dose groups for one menstrual cycle (4-6 weeks). Five animals per group received an IVR with in vitro release rates of dose A -C (Table I) . ATZ showed maximum concentrations at a t max between 27 and 48 h (Fig. 3) . The steady state plasma concentration (C ss ) was calculated as mean concentration of all time points between 24 h and the last measured time point (ca. 30 days). Only animals with data for at least 2/3 of the time points that were above the LLOQ were included in these analyses. For the calculation of the mean value, an individual data point below the LLOQ was substituted by half of the LLOQ (only for dose A). After IVR insertion, Css was achieved after 27-48 h (t max in Fig. 3 ). Mean C ss values were 0.3 + 0.12 mg/l (dose A), 1.4 + 0.55 mg/l (dose B) and 5.9 + 0.89 mg/l (dose C) (Table II) . C ss values normalized by the mean in vitro release rate (dose normalized, see Table II ) indicated dose linearity.
In vivo release rates from the IVRs were calculated by two methods. (i) Based on in vivo plasma levels the in vivo release rate is the product of Css and the in vivo CL of ATZ in cynomolgus monkeys (0.58 l/h/kg) and was calculated to be 16 + 5.4 mg/day (dose A), 66 + 24 mg/day (dose B) and 278 + 43 mg/day (dose C) (Tables I and II) . (ii) Based on the ex vivo ring residual drug content measured in the rings at the end of the study the mean in vivo release rates for the three treatment groups were calculated to be 15 mg/day (dose A), 54 mg/day (dose B) and 277 mg/day (dose C), respectively, demonstrating a good match of the two methods.
The study also served to monitor pharmacodynamic effects of ATZ applied intravaginally. Effects on plasma hormone levels as well as ovarian histology were assessed. A trend to a decrease in E 2 plasma levels was observed in the dose C group during the complete menstrual cycle but statistical significance was reached only in the proliferative phase (Fig. 4B) . One animal of the dose B group had elevated E 2 plasma level during the whole study compared with the other animals of the group (Fig. 3A-C) ; however, overall dose B group showed no significant increases in E 2 level during the proliferative and secretory phase. No treatment-dependent changes in E1, progesterone, FSH, LH, testosterone and androstenedione-levels have been observed (Table III) . In addition, twice weekly monitoring of the ovary with ultrasound confirmed that no treatment-related changes, including ovarian cyst formation, could be observed in any of the dose groups.
Discussion
The purpose of the present study was to show the compatibility of ATZ with a polymer-based vaginal drug delivery system, to get first insights into the in vitro and in vivo release, and to investigate the pharmacodynamic effects of intravaginally administered ATZ in a relevant preclinical endocrine model. One additional objective was to investigate whether it is possible to decrease systemic E2 levels without inducing counter regulation by the hypothalamic -pituitary -gonadal axis (HPG axis), a known effect of aromatase inhibitors, if applied to premenopausal women (Tredway et al., 2004) .
Compatibility and sustained release of a drug from an IVR are the prerequisites for its further development with this technology. A sustained in vitro release was achieved for the ATZ IVRs with an acceptable decline of the release rate during the first 28 days (Table II , d1-d4 versus d24-d28) of about 25% for the highest dose. The observation of an overall moderate decline of the release rate during the test period was confirmed by the almost constant in vivo ATZ plasma concentrations (Fig. 3) . With the help of the plasma clearance (CL) of ATZ in cynomolgus monkeys which was calculated after intravenous administration, the in vivo release rate of intravaginally administered ATZ was calculated as the product of the mean of the observed plasma concentrations (Css) and the CL. A nearly complete absorption of the drug released from the IVRs into the systemic circulation can be assumed (Table I) based on the observed in vivo release rates that represent 91 -103% of the corresponding in vitro release rates (mean of d2-d30). These results underline the advantage to apply drugs to the vagina by IVR as an alternative to the commonly used orally route by circumvention of the liver first pass and the achievement of constant drug plasma levels due to the constant Anastrozole effects in cynomolgus monkey drug release from the IVR. Furthermore, the avoidance of a peak in drug levels may result in a reduction of the drug side effect potential like a Cmax-induced counter regulation and, thereby, potentially increases the safety of the administered drug. In this manner it may be possible to apply higher dosages. The choice of a relevant preclinical endocrine model to study intravaginally administered drugs that influence the HPG axis is mandatory. The model should have a similar reproductive system to women including anatomy of the vagina and the endocrine control mechanism. The cynomolgus monkey fulfills these requirements, in that the morphology of the reproductive tract, the endocrine system, the control of unilateral singleegg ovulation and the reproductive cycle duration of 30 days are similar to women Weinbauer et al., 2008) .
ATZ released from IVRs of the dose group C decreased the systemic E 2 level significantly during the proliferative phase in the cynomolgus monkeys (Fig. 4) without stimulating the HPG axis, as FSH levels were similar to the levels of the control group. Furthermore, unchanged progesterone values indicate ovulation in all groups (Table III) , and no follicular cysts were detected during treatment. It has been known for years that in premenopausal women an induced E 2 decrease stimulates the HPG axis to raise the FSH level with subsequent ovarian stimulation, follicular growth and enhanced E 2 synthesis (Messinis, 2006) . The data collected in this study suggest that an E 2 decline only stimulates the HPG axis if the hormone level falls below a particular threshold. However, the current study was limited to three dose groups in which only the highest dose decreased the E 2 level. Hence, additional research with IVRs releasing higher amounts of ATZ is required to define the threshold for an ATZ-dependent ovarian stimulation in primates. The therapeutic clinical use of AIs is currently restricted to estrogen-dependent diseases in post-menopausal women like breast cancer. AIs have only been used experimentally to date, for example in the treatment of endometriosis. When AIs are administered to premenopausal women, the production of E2 is suppressed, causing an increase in gonadotrophin levels and stimulation of ovarian function. This may lead to the development of Figure 4 Estradiol (E 2 ) levels during one menstrual cycle illustrated by the AUC (area under the curve) of (A) the complete cycle, (B) the proliferative phase and (C) in the secretory phase (n ¼ 4). Treatment of cynomolgus monkeys with ATZ IVRs decreases E 2 levels predominantly within the proliferative phase. CD, cycle day. Data are expressed as mean + SD. Two-sided t-test dose versus vehicle * ¼ P-value , 0.05. ovarian cysts, and in studies where AIs are administered to women of reproductive age, they are often used in combination with therapies that down-regulate ovarian function and thereby prevent ovarian cyst formation, such as progestins or combined oral contraceptives (Amsterdam et al., 2005; Ferrero et al., 2009) . The data of the present study indicated that ATZ can be applied to premenopausal monkeys without causing ovarian stimulation questioning the requirement of co-dosing ATZ with therapies that down-regulate ovarian function. This finding may disclose new possibilities for the use of ATZ in the treatment of gynecological diseases of premenopausal women.
There are several reasons to administer ATZ in premenopausal women for estrogen-depended diseases such as endometriosis. First, aromatase has been shown to be locally overexpressed in endometriotic lesions (Bulun et al., 2000) , possibly explaining treatment failures by drugs interfering only with ovarian estrogen production. Second, AIs alone are able to interfere with both, ovarian and endometriotic estrogen production. Evidence for therapeutic efficacy of AIs in endometriosis was shown in several exploratory clinical trials (for a review of the clinical experience, see (Ferrero et al., 2011) ), particularly in patients refractory to other treatments (Amsterdam et al., 2005) . The findings in this study may enhance the repertoire for future drug development by application of ATZ by IVRs for human diseases.
In conclusion, the present study documents the feasibility of IVR administration of the AI ATZ. The release rate from IVRs is sufficient and in a range that supports feasibility of IVR administration of ATZ as a new approach for long-term therapy of estrogen-dependent diseases such as endometriosis. IVR administration of ATZ is expected to allow a constant AI exposure that is sufficient to block aromatase particularly locally in endometriotic lesions and to reduce only moderately plasma to avoid counter regulation by the HPG axis.
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